Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.The company has 3 R&D and 5 manufacturing facilities.
What Alembic files
- Others153
- Updates64
- Investor Meet40
- Important39
- Dividend/Bonus19
- Board Meeting15
Confirmation of Redemption/Payment of Interest and Principal
Successful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited s Bioequivalence Facility in Vadodara, Gujarat
Alembic Pharmaceuticals has expanded its global footprint by incorporating a new wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai. This move aims to explore fresh business opportunities and strengthen the international promotion, sale, and distribution of the company’s pharmaceutical portfolio through a cash investment.
Alembic Pharma announced record dates for the maturity of its Commercial Papers (CPs) totaling ₹750 Cr. If you hold these CPs, record dates fall between September 10-25, 2026, for maturities from September 11-28, 2026. This determines eligibility for your maturity payment.
Alembic Pharmaceuticals management has scheduled one-to-one meetings with various investors and analysts, including Dolat Capital, Equirus Securities, ICICI Securities, Ashmore, and HSBC, on September 1 and 2. These engagements will not involve sharing any unpublished price sensitive information.